- Report
- May 2024
- 139 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
Pancreatic Ductal Carcinoma (PDC) is a type of cancer that affects the pancreas. It is the most common form of pancreatic cancer and is often difficult to treat. As a result, there is a need for effective drugs to treat PDC. The Pancreatic Cancer Drugs market is composed of a variety of drugs that are used to treat PDC. These drugs include chemotherapy, targeted therapy, immunotherapy, and other treatments. The drugs are designed to target the cancer cells and reduce the size of the tumor. Additionally, they can help to reduce the side effects of chemotherapy and other treatments.
The Pancreatic Cancer Drugs market is highly competitive, with many companies offering different treatments. Some of the major players in the market include Roche, Merck, Bristol-Myers Squibb, AstraZeneca, and Novartis. Additionally, there are many smaller companies that are developing new treatments for PDC. Show Less Read more